Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral
KEYWORDS: risk, aspirin, rivaroxaban, people, events, plus, disease, plus aspirin, treatment, bleeding, rivaroxaban plus, committee, artery, artery disease, ischaemic

is, people with a high risk of ischaemic events as defined by the inclusion criteria of the trial. The committee recalled that the clinical benefits and risks associated with rivaroxaban plus aspirin are finely balanced (see section 3.4 and section 3.5). The committee noted that rivaroxaban plus aspirin is contraindicated in cases of active clinically significant bleeding and in people with lesions or conditions considered to be a significant risk factor for major bleeding. It agreed that a person's risk of bleeding should be assessed before rivaroxaban is considered as a treatment option. The decision to start treatment should only be taken after an informed discussion about the risks and benefits of rivaroxaban, weighing up the risk of ischaemic events against the bleeding risk. The committee concluded that rivaroxaban should only be considered a treatment option for people at high risk of ischaemic events as defined by the inclusion criteria of COMPASS. Comparators Clopidogrel is not a relevant comparator for the overall COMPASS population 3.7 The company did not present evidence for rivaroxaban plus aspirin compared with clopidogrel. The clinical experts explained that clopidogrel is the preferred antiplatelet treatment for people with peripheral artery disease (based on NICE's technology appraisal
